Altaris to Acquire Simulations Plus in a $375 Million Cash Deal

Altaris, LLC has announced a definitive agreement for the acquisition of Simulations Plus, Inc. (SLP) in a transaction valued at $375 million.

Transaction Overview:

As per the terms of the agreement, Altaris, LLC will acquire all outstanding shares of Simulations Plus, Inc. at $18.50 per share, in cash. This price reflects a premium of 13.01% over the closing price of Simulations Plus, Inc. on the day before the announcement.

About the Companies:

Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $9+ billion of equity capital.

Simulations Plus develops software and provides consulting services that help pharmaceutical and biotechnology companies accelerate drug discovery, development, and regulatory approvals. Its AI-enabled modeling and simulation platforms, including GastroPlus, MonolixSuite, ADMET Predictor, and DILIsym, are used by life sciences companies and regulatory agencies worldwide.

Deal Specifics and Expected Timeframe:

The transaction is anticipated to close in the calendar fourth quarter of 2026.

At or about the closing of the transaction, Altaris anticipates the company will be combined with Chemical Computing Group (“CCG”), an existing Altaris portfolio company that provides advanced molecular design software to customers across the pharmaceutical, chemical and materials sectors.

In this deal, Simulations Plus, Inc. was advised by Morgan Stanley on financial matters and received legal counsel from Procopio Cory Hargreaves & Savitch. Altaris, LLC was guided by Truist Securities / J.P. Morgan Securities for financial advice and Bass, Berry & Sims / Kirkland & Ellis provided legal representation.

The stock involved in this transaction is optionable.

Altaris is acquiring Simulations Plus at 4.09 times its sales and 20.73 times its EBITDA.

M&A Deal Metrics:

For a comprehensive analysis of this M&A transaction, please refer to the Deal Metrics page here:

Deal Metrics for the acquisition of Simulations Plus, Inc. (SLP) by Altaris, LLC

The Deal Metrics page for each merger or acquisition includes:

• A graphical representation of the merger’s spread history from announcement through completion or failure.
• A detailed timeline of the merger, including the expiration of the HSR period, regulatory approvals, shareholder votes, and more.
• News and SEC filings related to the merger.
• A chronology of deal updates.
• And much more.

Disclaimer: This article is intended for informational purposes only. We encourage readers to conduct their own research and due diligence before buying or selling any securities mentioned. We do not guarantee the completeness or accuracy of the content or data provided in this article.